TICKERNERD
Menu
BDTXBDTXHealthcare · Biotechnology

BDTX Stock Forecast: Black Diamond Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.21
+2.79% on the day

The 9 Wall Street analysts covering Black Diamond Therapeutics, Inc. hold a median 12-month price target of $10 — +352.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$127.0M
Ticker Nerd rank
55 / 100
Median analyst target
$10
Analysts covering
9
Total return, dividends reinvested
1W
+9.4%
1M
+18.2%
YTD
−9.1%
1Y
−18.5%
From 52W high
−54.6%
From 52W low
+37.3%
$1.61
$4.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BDTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Black Diamond Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
81
Accruals
80
Size
73
Issuance
72
Revisions
56
Value
51
Volatility
33
Momentum
19
Growth
9

Quality (81): The business earns solid, repeatable profits on what it owns.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BDTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BDTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26BDTXHigh $14Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $8Median $10High $14

The green dot is the last close — the median target sits +352.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Apr 2026BTIGMaintainsBuy$10 → $11
17 Mar 2026WedbushMaintainsOutperform—
16 Jan 2026Piper SandlerMaintainsOverweight—
4 Dec 2025GuggenheimDowngradeNeutral—
18 Nov 2025Piper SandlerAssumesOverweight$9.00
16 Oct 2025StifelReinstatesBuy$8.00
1 Oct 2025Freedom BrokerInitiatesBuy—
4 Sept 2025GuggenheimInitiatesBuy—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
1 July 2025Raymond JamesReinstatesOutperform$11
18 Mar 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025StifelMaintainsBuy—
6 Nov 2024HC Wainwright & Co.ReiteratesBuy—
9 Oct 2024HC Wainwright & Co.ReiteratesBuy—
8 Oct 2024WedbushReiteratesOutperform—
24 Sept 2024HC Wainwright & Co.ReiteratesBuy—
23 Sept 2024Piper SandlerMaintainsOverweight—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
10 Sept 2024WedbushReiteratesOutperform—
4 Sept 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BDTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Black Diamond Therapeutics, Inc. (BDTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.2×

Cheaper than 63% of US stocks

Price / sales
1.8×

Cheaper than 56% of US stocks

Price / book
1.3×

Cheaper than 63% of US stocks

EV / EBITDA
−0.8×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
28.4%

Higher than 86% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.2%

Higher than 25% of US stocks

Return on assets
−19.1%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BDTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BDTXBlack Diamond Therapeutics, Inc.$127.0M
55
VANIVivani Medical, Inc.$124.5M
40
ANIXAnixa Biosciences, Inc.$124.4M
85
CBUSCibus, Inc.$129.5M
33
GUTSFractyl Health, Inc.$123.7M
30
VTVTvTv Therapeutics, Inc.$131.0M
77
MISTMilestone Pharmaceuticals, Inc.$131.3M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Black Diamond Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BDTX news & analysis

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 5 Aug 2026neutral

Black Diamond Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The clinical-stage oncology company, which is developing MasterKey therapies including the EGFR inhibitor silevertinib, announced the results on August 5, 2026.

Why it matters — BDTX watchers would want to track the company's latest financial results and corporate update for signs of progress on its oncology pipeline, including silevertinib.

FAQ

Frequently asked questions about BDTX stock

What is the BDTX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Black Diamond Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BDTX stock a buy right now?

Of the 9 analysts covering Black Diamond Therapeutics, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Black Diamond Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BDTX?

As at 22 Aug 2026, Black Diamond Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (81 of 100).

Will BDTX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +352.5% from the last close, and Ticker Nerd's factor model ranks Black Diamond Therapeutics, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BDTX stock forecast for 2030?

No analyst covering Black Diamond Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.

How has BDTX stock performed over the past year?

Black Diamond Therapeutics, Inc. returned -18.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Black Diamond Therapeutics, Inc. do?

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers.

What is the latest news on BDTX?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update". Black Diamond Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The clinical-stage oncology company, which is developing MasterKey therapies including the EGFR inhibitor silevertinib, announced the results on August 5, 2026.

Company

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers. These therapies aim to address a broad spectrum of tumors, overcome resistance mechanisms, minimize wild-type mediated toxicities, and achieve brain penetrance for treating central nervous system diseases, including brain metastases and primary brain tumors. The company's lead candidate, silevertinib (BDTX-1535), is a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor advancing in a Phase 2 trial for frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations and in trials for glioblastoma (GBM) with EGFR alterations. Black Diamond Therapeutics has also licensed BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting RAF/RAS-mutant solid tumors, to Servier for further development. Headquartered in Cambridge, Massachusetts, and founded in 2014, the company focuses on precision oncology to meet unmet needs in mutation-driven cancers.

CEO Dr. Mark A. Velleca M.D., Ph.D. · 21 employees · United States · https://www.blackdiamondtherapeutics.com